Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 39

1.

Possible participation of receptor for advanced glycation end products (RAGE) in the origin of cancer stem cells in diabetic patients with colon cancer.

Hu X, Cheng Y.

Med Hypotheses. 2013 May;80(5):620-3. doi: 10.1016/j.mehy.2013.02.004. Epub 2013 Mar 5.

PMID:
23466064
2.

The biology of RAGE and its ligands: uncovering mechanisms at the heart of diabetes and its complications.

Yan SF, Barile GR, D'Agati V, Du Yan S, Ramasamy R, Schmidt AM.

Curr Diab Rep. 2007 Apr;7(2):146-53. Review.

PMID:
17425919
3.
4.

AGE-RAGE system and carcinogenesis.

Abe R, Yamagishi S.

Curr Pharm Des. 2008;14(10):940-5. Review.

PMID:
18473843
5.

Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications.

Yan SF, Ramasamy R, Schmidt AM.

Nat Clin Pract Endocrinol Metab. 2008 May;4(5):285-93. doi: 10.1038/ncpendmet0786. Epub 2008 Mar 11. Review.

PMID:
18332897
6.

RAGE and RAGE ligands in cancer.

Logsdon CD, Fuentes MK, Huang EH, Arumugam T.

Curr Mol Med. 2007 Dec;7(8):777-89. Review.

PMID:
18331236
7.

Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes.

Stern DM, Yan SD, Yan SF, Schmidt AM.

Ageing Res Rev. 2002 Feb;1(1):1-15. Review.

PMID:
12039445
8.

RAGE: a journey from the complications of diabetes to disorders of the nervous system - striking a fine balance between injury and repair.

Rong LL, Gooch C, Szabolcs M, Herold KC, Lalla E, Hays AP, Yan SF, Yan SS, Schmidt AM.

Restor Neurol Neurosci. 2005;23(5-6):355-65. Review.

PMID:
16477098
9.

Receptor for advanced glycation end products and its ligands: a journey from the complications of diabetes to its pathogenesis.

Kim W, Hudson BI, Moser B, Guo J, Rong LL, Lu Y, Qu W, Lalla E, Lerner S, Chen Y, Yan SS, D'Agati V, Naka Y, Ramasamy R, Herold K, Yan SF, Schmidt AM.

Ann N Y Acad Sci. 2005 Jun;1043:553-61. Review.

PMID:
16037278
10.

The RAGE axis and endothelial dysfunction: maladaptive roles in the diabetic vasculature and beyond.

Ramasamy R, Yan SF, Schmidt AM.

Trends Cardiovasc Med. 2005 Oct;15(7):237-43. Review.

PMID:
16226677
11.

Roles of the receptor for advanced glycation endproducts in diabetes-induced vascular injury.

Yonekura H, Yamamoto Y, Sakurai S, Watanabe T, Yamamoto H.

J Pharmacol Sci. 2005 Mar;97(3):305-11. Epub 2005 Mar 5. Review.

12.

The role of AGEs in cardiovascular disease.

Jandeleit-Dahm K, Cooper ME.

Curr Pharm Des. 2008;14(10):979-86. Review.

PMID:
18473849
13.
14.

AGEs, RAGE, and diabetic retinopathy.

Zong H, Ward M, Stitt AW.

Curr Diab Rep. 2011 Aug;11(4):244-52. doi: 10.1007/s11892-011-0198-7. Review.

PMID:
21590515
15.
16.

Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes.

Yamagishi S.

Exp Gerontol. 2011 Apr;46(4):217-24. doi: 10.1016/j.exger.2010.11.007. Epub 2010 Nov 25. Review.

PMID:
21111800
17.

Fueling inflammation at tumor microenvironment: the role of multiligand/RAGE axis.

Rojas A, Figueroa H, Morales E.

Carcinogenesis. 2010 Mar;31(3):334-41. doi: 10.1093/carcin/bgp322. Epub 2009 Dec 22. Review.

PMID:
20028726
19.

Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications.

Yamagishi S, Nakamura K, Matsui T, Ueda S, Fukami K, Okuda S.

Expert Opin Investig Drugs. 2008 Jul;17(7):983-96. doi: 10.1517/13543784.17.7.983 . Review.

PMID:
18549336
20.

Advanced glycation end products (AGEs) and their receptor (RAGE) system in diabetic retinopathy.

Yamagishi S, Nakamura K, Matsui T.

Curr Drug Discov Technol. 2006 Mar;3(1):83-8. Review.

PMID:
16712466

Supplemental Content

Support Center